MARKET

QNCX

QNCX

Quince
NASDAQ
1.150
-0.030
-2.54%
After Hours: 1.160 +0.01 +0.86% 19:55 05/15 EDT
OPEN
1.180
PREV CLOSE
1.180
HIGH
1.180
LOW
1.140
VOLUME
595.63K
TURNOVER
--
52 WEEK HIGH
45.50
52 WEEK LOW
0.8000
MARKET CAP
18.75M
P/E (TTM)
-0.0686
1D
5D
1M
3M
1Y
5Y
1D
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
PUBT · 4d ago
Weekly Report: what happened at QNCX last week (0504-0508)?
Weekly Report · 5d ago
BRIEF-Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Reuters · 05/08 10:24
ALPHABET DISSOLVES SHARE STAKE IN REPLIGEN - SEC FILING
Reuters · 05/08 10:03
Largest borrow rate increases among liquid names
TipRanks · 05/05 13:10
Weekly Report: what happened at QNCX last week (0427-0501)?
Weekly Report · 05/04 09:42
Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk
TipRanks · 04/28 22:04
Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
PUBT · 04/28 21:05
More
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Webull offers Quince Therapeutics Inc stock information, including NASDAQ: QNCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QNCX stock methods without spending real money on the virtual paper trading platform.